Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 83,333 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $21.54, for a total transaction of $1,794,992.82. Following the completion of the sale, the chief executive officer now owns 235,837 shares in the company, valued at $5,079,928.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Nektar Therapeutics (NASDAQ:NKTR) traded down 0.89% during trading on Friday, reaching $22.27. 880,200 shares of the company’s stock were exchanged. The stock’s market capitalization is $3.48 billion. The company’s 50 day moving average price is $20.29 and its 200-day moving average price is $19.24. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $24.88.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.04. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The company had revenue of $34.60 million for the quarter, compared to analysts’ expectations of $33.64 million. During the same period in the previous year, the firm posted ($0.36) earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, equities analysts expect that Nektar Therapeutics will post ($0.94) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Nektar Therapeutics (NKTR) CEO Sells 83,333 Shares of Stock” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/08/insider-selling-nektar-therapeutics-nktr-ceo-sells-83333-shares-of-stock.html.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. grew its position in Nektar Therapeutics by 0.9% during the second quarter. BlackRock Inc. now owns 20,221,479 shares of the biopharmaceutical company’s stock valued at $395,330,000 after purchasing an additional 185,933 shares in the last quarter. Vanguard Group Inc. grew its position in Nektar Therapeutics by 3.0% during the second quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock valued at $273,893,000 after purchasing an additional 401,914 shares in the last quarter. State Street Corp grew its position in Nektar Therapeutics by 11.3% during the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after purchasing an additional 447,023 shares in the last quarter. Bank of New York Mellon Corp grew its position in Nektar Therapeutics by 0.6% during the second quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock valued at $41,812,000 after purchasing an additional 12,730 shares in the last quarter. Finally, FMR LLC grew its position in Nektar Therapeutics by 42.4% during the first quarter. FMR LLC now owns 1,947,644 shares of the biopharmaceutical company’s stock valued at $45,711,000 after purchasing an additional 580,341 shares in the last quarter. 95.15% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently issued reports on NKTR shares. Roth Capital set a $31.00 price objective on shares of Nektar Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 11th. William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. BidaskClub raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Jefferies Group LLC reissued a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a research note on Friday, July 21st. Finally, ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. Nektar Therapeutics presently has an average rating of “Buy” and an average price target of $26.10.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.